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Introduction
The goal of precision medicine is to develop prevention and 
treatment strategies that take into account individual character-
istics. As Collins and Varmus stated, “The prospect of applying 
this concept broadly has been dramatically improved by recent 
developments in large-scale biologic databases (such as the 
human genome sequence), powerful methods for character-
izing patients (such as proteomics, metabolomics, genomics, 
diverse cellular assays, and mobile health technology), and 
computational tools for analyzing large sets of data.” With this 
words in mind, US President Obama gave his strong endorse-
ment in launching the 2015 Precision Medicine initiative to 
capitalize on these developments1,2. Here, we aim to quantify the 
proportion of interventions that may beneit from this idea.
The fundamental problem of causal inference is that for each 
patient in a parallel group trial, we can know the outcome for 
only one of the interventions. That is, we observe their responses 
either to the new treatment or to the control, but not both. By 
experimentally controlling unknown confounders through 
randomization, a clinical trial may estimate the averaged causal 
effect. In order to translate this population estimate into effects 
for individual patients, additional assumptions are needed. 
The simplest and strongest one is that the effect is constant. 
Panels A and B in Figure 13–12 represent two scenarios with a 
common effect in all patients, although it is null in the irst case. 
Following Holland13, this assumption has the advantage of 
making the average causal effect relevant to each patient. All other 
scenarios (Figure 1, Panels C to F) require additional parameters 
to fully specify the treatment effect.
As an example, the 10 clinical trials published by the jour-
nal Trials in October 2017 (Supplementary File 1: Table S1) 
were designed without explicitly allowing for an effect that was 
not constant within the study population. Furthermore, all their 
analyses intended to estimate just an average effect with no 
indication of any possible interaction with baseline variables 
(Figure 1, Panels C and E), nor did they discuss any random 
variability for the treatment effect (Figure 1, Panels D and F). 
Therefore, without further speciications, it seems that they 
were either hoping for the treatment effect to be the same for all 
patients or assuming that it was not useful to try and investigate 
this. As a contrary example, Kim et al.14 designed their trial to 
test an intervention for: 1) non-inferiority in the overall popu-
lation and 2) superiority in the subgroup of patients with high 
epidermal growth factor receptor expression.
The variability of a clinical trial outcome measure is relevant 
because it conveys important information about whether or not 
precision medicine is achievable. Does variance come only 
from unpredictable sources of patient variability? Or should it 
also be attributed to different treatment effects that require more 
precise prescription rules15–17? One observable consequence of 
a constant effect is that the treatment will not affect variability, 
and therefore the outcome variances in both arms should be 
equal (“homoscedasticity”).
Below, we will elucidate whether the comparison of observed 
variances may shed some light on the non-observable individual 
treatment effect.
Our objectives are, irst, to compare the variability of the main 
outcome between arms in parallel randomized controlled tri-
als published in medical journals; and, second, to provide a 
rough estimate of the proportion of studies that could poten-
tially beneit from precision medicine. To assess the consistency 
of results, we also explore the evolution of the variability of the 
treated arm over time (from baseline to the end of the study).
Methods
Population
Our target population was parallel, randomized controlled trials 
with numerical primary endpoint. The trials should provide 
enough information to assess two homoscedasticity assump-
tions in the primary endpoint: between arms at trial end; and 
baseline to outcome over time in the treated arm. Therefore, 
baseline and inal SDs for the main outcome were necessary 
or, lacking those, we required at least one measure that would 
allow us to calculate them (variances, standard errors or mean 
conidence intervals).
Data collection
Using the Medline database, we selected articles on parallel 
clinical trials from the years 2004, 2007, 2010 and 2013 with 
the following criteria: “AB (clinical trial* AND random*) AND 
AB (change OR evolution OR (difference AND baseline))” [The 
word “difference” was paired with “baseline” because the initial 
purpose of the data collection (although it was subsequently 
modiied) was to estimate the correlation between baseline 
and inal measurements]. The rationale behind choosing these 
years was to have a global view of the behavior of the studies 
over a whole decade. For the years 2004 and 2007, we selected 
all papers that met the inclusion criteria. However, we retrieved 
a greater number of articles from our search for the years 2010 
and 2013 (478 and 653, respectively); therefore, we chose a 
random sample of 300 papers (Section II in Supplementary File 1).
Data were collected by two researchers (NM, MkV) in two 
phases: 2004/2007 and 2010/2013. Later, two statisticians (JC, 
MtV) veriied the data and made them accessible to readers 
through a Shiny application and through the Figshare repository18.
Variables
Collected variables were: baseline and outcome SDs; experi-
mental and control interventions; sample size in each group; 
medical ield according to Web of Science (WOS) classiication; 
main endpoint; indication; type of disease (chronic versus acute); 
endpoint type (measured versus scored); intervention type 
(pharmacological versus non-pharmacological); improvement 
      Amendments from Version 4
- We have modified Figure 2 (flowchart) by including standard 
percentages.
- Different datasets mentioned in Table S4 of the Supplementary 
Material have been named in order to avoid ambiguities.
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Figure 1. Scenarios representing fictional trials using 8 participants with systolic blood pressure as the primary endpoint. Because 
of the random allocation to one of two treatment arms, we will observe only one of the two potential outcomes for each patient: either under 
T or under C. Fully saturated colors represent observed systolic blood pressure (SBP) values, and transparent squares represent missing 
potential SBP values. The line slope indicates the individual non-observable effect for each patient. Densities are the potential distributions of 
the outcome in each group: As both random samples come from the same target population, the average causal effect is estimable without 
bias. Panel A shows the potential outcome values that we could obtain if there were not any treatment effect; as the intervention has no effect 
at all, both groups have the same distribution (i.e., mean and variance). Panel B shows the scenario of a constant effect, meaning that the 
intervention lowers the SBP by a single value in every patient and thus implying the same variability in both arms. For instance, the study from 
Duran-Cantolla et al.3 compared the 24-hour SBP in 340 patients randomized to either continuous positive airway pressure (CPAP) or sham–
CPAP, and they observed a greater decrease of 2.1 mmHg (95% CI from 0.4 to 3.7) in the intervention group compared to the control group. 
Furthermore, baseline standard deviations (SDs) were 12 and 11; and final SDs were 13 for both groups. Therefore, their results fully agree 
with the trial design’s assumption of a constant effect (scenario B) and nothing contradicts the inference that each patient exhibits a constant 
reduction of 2.1mmHg, although uncertainty from sampling makes the results compatible with a constant effect that lies somewhere between 
0.4 and 3.7. Panel C represents a situation with 2 different effects in 2 subpopulations (“treatment by subgroup interaction”). Although the 
effects are identical within them, the observable distribution in the treated arm would have higher variability. Here, finer eligibility criteria for 
classifying patients in those subpopulations might allow us to assume a constant effect again. In Panel D, the treatment has a variable effect 
in each patient, resulting also in greater variability within the treated arm but without any subgroup sharing a common effect. The results are 
poorly predictive about the effects on future patients. In the study by Kojima et al.4, the primary outcome measure was the 3-hour postprandial 
area under the curve of apolipoprotein B48, with outcome SDs being, respectively, 0.78 and 0.16 in the treated and reference arms, thus 
showing an outcome variance ratio of 23.77. This is compatible with different treatment effects that could need additional refinements through 
precision medicine, since a greater variance in the treated arm indicates that “the interpretation of the main treatment effect is controversial”5. 
In that case, guidelines for treating new patients should be based either on additional eligibility criteria (“precision medicine”, panel C) or on 
n-of-1 trials (“individualized medicine”, panel D)6–10. W. S. Gosset already highlighted this “treatment by patient interaction” in his 1908 paper, 
where he introduced the Student t-distribution11. Alternatively, interactions can result in smaller variances in the treated arm. Panel E shows a 
different effect in 2 subgroups; but the variability is now reduced, thus indicating that the best solution would be to identify the subpopulations 
in order to refine the selection criteria. In Panel F, the treatment again has a variable effect on each patient; but unlike Panel D, in this case 
the consequence is less variability within the treated arm. In the study from Kim et al.12, the primary endpoint was the PTSD Checklist–Civilian 
Version (PCL-C). This scale is based on the sum of 17 Likert-scale symptoms, ranging from 17 (perfect health) to 85 (worst clinical situation). 
At the end of the trial, the respective outcome SDs were 16 and 3 for the control and treated arms, meaning that variance was reduced around 
28 times. This situation can correspond to scenarios E or F, and it merits statistical consideration, that is beyond the scope of this paper.
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direction (positive versus negative); and whether or not the main 
effect was statistically signiicant.
For studies that reported more than one numerical endpoint and 
failed to clarify which endpoint was the primary endpoint, the 
latter was determined using the following hierarchical criteria: 
(1) objective or hypothesis; (2) sample size determination; 
(3) main statistical method; (4) irst numerical variable reported 
in results.
In the same way, the choice of the “experimental” arm was 
determined depending on its role in the following sections of 
the article: (1) objective or hypothesis; (2) sample size deter-
mination; (3) rationale in the introduction; (4) irst comparison 
reported in results (in the case of more than two arms).
Statistical analysis
We assessed homoscedasticity between treatments and over 
time. For the former, our main analysis compared the outcome 
variability between treated (T) and control (C) arms at the end 
of the trial. For the latter, we compared the variability between 
outcome (O) and its baseline (B) value for the treated arm.
Three different methods were used to compare the variances: 
1) a random-effects model; 2) a heuristic procedure based on 
the heterogeneity obtained from the previous random-effects 
model; and 3) a classical test for equality of variances.
To distinguish between the random sampling variability and 
heterogeneity, we itted a random-effects model. The response 
was the logarithm of the outcome variance ratio at the end of 
the trial. The covariates were the study as a random effect, while 
the logarithm of the variance ratio at baseline served as a ixed 
effect19.
The main itted model for between-arm comparison was:
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). The parameter µ is the logarithm of the average variance 
ratio across all the studies; s
i
 represents the heterogeneity of 
the between-study effect associated with study i and having 
variance τ2; β is the coeficient for the linear association with the 
baseline variance ratio; and e
i
 represents the intra-study random 
errors with variance vi2 .
The parameter µ represents a measure of the imbalance 
between the variances at the end of the study, which we call 
heteroscedasticity.
The estimated value of τ2 provides a measure of heterogene-
ity, that is, to what extent the value of µ is applicable to all 
studies. The larger τ2 is, the lesser the homogeneity.
The percentage of the response variance explained by the 
differences among studies in respect to the overall variance is 
measured by the I2 statistic20. That is:










v2 is the mean of the error variances 
iv
2.
An analogous model was employed to assess the homoscedas-
ticity over time. As there is only one available measure for each 
study, it is not possible to differentiate both sources of variability: 
(i) within-study or random variability; and (ii) heterogeneity. To 
isolate the second, the irst was theoretically estimated using either 
the delta method, in the case of comparison between arms, or some 
approximation, in the case of comparison over time (see details in 
Sections VI and VII of Supplementary File 1). Thus, the within-
study variance was estimated using the following formulas:






V log (between arms)
V n n
  
  = + 
− −  









V log log (over time)
V n n n
     2⋅     = − ⋅ + 
− −     
Funnel plots centered at zero are reported in order to help inves-
tigate asymmetries. They represent the variance ratios as a 
function of their standard errors. The irst and main analysis 
considers the studies outside the triangle delimited by ± 2 times 
the standard error to be those that have statistically signiicant 
differences between variances.
The second analysis is heuristic. In order to obtain a reference 
value for τ2 in the absence of treatment effect, we irst mod-
eled the baseline variance ratio as a response that is expected to 
have heterogeneity equal to 0 due to randomization – provided 
no methodological impurities are present (e.g., considering the 
outcomes obtained 1 month after the start of treatment to be 
the baseline values). This reference model allows us to know 
the proportion of studies in the previous models that could 
increase heterogeneity over levels that are incompatible with a 
constant effect situation. (Section III in Supplementary File 1). 
Speciically, studies with larger discrepancies in variances were 
removed one by one until the estimated value of τ was as close 
as possible to that of the reference model. These deleted stud-
ies were considered to be those that had signiicantly differ-
ent variances, perhaps because the experimental treatment 
either increased or decreased the variance. From now on, the 
complete dataset and the resulting dataset after removing the 
abovementioned studies will be called CDB (complete dataset) 
and RDB (reduced dataset) for between-arm comparison and 
CDO (Complete) and RDO (Reduced) for over-time comparison.
Thirdly, as an additional sensitivity analysis, we also assessed 
homoscedasticity in each single study by using tests for com-
paring variances: (a) between outcomes in both arms with an 
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F-test for independent samples; and (b) between baseline and 
outcome in the treated arm with a test for paired samples21 
when the variance of the paired difference was available. All 
tests were two-sided (α=5%).
Several subgroup analyses were carried out according to the 
statistical signiicance of the main treatment effect and to the 
different types of outcomes and interventions.
All analyses were performed with the R statistical package 




A total of 1214 articles were retrieved from the search. Of 
those papers, 542 (44.6%) belong to the target population and 
208 (17.1%) contained enough information to enable us to 
conduct the analysis (Figure 2).
The majority of the selected studies were non-pharmacologi-
cal (122, 58.6%); referred to chronic conditions (101, 57.4%); 
had a continuous outcome measured with units (132, 63.8%) 
instead of a constructed scale; had an outcome that was meas-
ured (125, 60.1%) rather than assessed; and had lower values 
of the outcome indicating positive evolution (141, 67.8%). 
Regarding the primary objective of each trial, the authors found 
statistically signiicant differences between arms (all of which 
favored the treated group) in 83 (39.9%) studies. Following the 
Web of Science criteria, 203 articles (97.6%) belonged to at least 
one medical ield. The main areas of study were: General & Inter-
nal Medicine (n=31, 14.9%), Nutrition & Dietetics (21, 10.1%), 
Endocrinology & Metabolism (19, 9.1%), and Cardiovascular 
System & Cardiology (16, 7.7%).
Figure 2. Flow-chart of the articles in the study. Percentages represent the number of papers with respect to the ones retrieved from the 
bibliographic search. The number of articles for each year (2004/2007/2010/2013) is specified in the second line of each box (separated by 
slashes). $300 papers were randomly selected for years 2010 and 2013. *Four papers were excluded because the variance of the change 
over time was inconsistent with both the baseline and final variances, which would lead to impossible absolute correlation estimates greater 
than 1. CDB and RDB are the datasets used in the main and heuristic analysis, respectively, for the between-arm comparison. CDO and RDO 
are the datasets used in the main and heuristic analysis, respectively, for the over-time comparison.
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Homoscedasticity
In descriptive terms, the average of the outcome variance ratio 
is 0.94, relecting lower variability in the treated arm. At the end 
of the study, 113/208 (54%, 95% CI, 47 to 61%) papers showed 
less variability in the treated arms (Supplementary File 1: 
Figure S1 and Figure S2). Among the treated arms, 111/208 
(53%, 95% CI, 46 to 60%) had less or equal variability at the 
end of follow-up than at the beginning (Supplementary File 1 : 
Figure S3 and Figure S4).
Based on the random-effects model (Supplementary File 1: 
Table S4, model 3 with CDB) the adjusted point estimate of 
the mean outcome variance ratio for comparison between 
arms (Treated to Control group) is 0.89 (95% CI 0.81 to 0.97). 
This indicates that treatments tend to reduce the variability of 
the patient’s response by about 11% on average. As for the com-
parison over time (Supplementary File 1 : Table S4, Model 6 with 
CDO), the average variability at the end of the studies is 14% 
lower than that at the beginning. Figure 3 shows the funnel plots 
derived from the random-effects models. The triangles delimit 
the 95% conidence regions of random variability. In the 
between-arm comparison, the studies (represented by the circles) 
to the right of the triangle have variances that are signii-
cantly larger in the treatment arm than in the control arm, while 
those on the left are signiicantly larger in the control arm. 
As for the over-time comparison, the studies to the right have a 
signiicantly higher variance at the end of the study in the treated 
group, while those on the left are signiicantly larger at the 
beginning of the study. Table 1 (random-effects method) shows 
the frequencies and percentages of the studies according to the 
classiication illustrated in these funnel plots.
The second heuristic analysis was motivated by the fact that the 
estimated baseline heterogeneity (τ2) was 0.31 (Supplementary 
File 1 : Table S4, Model 1 with CDB), which is a very high 
value that could be explained by methodological laws 
similar to those presented by Carlisle23. Fortunately, the exclu-
sion of the four most extreme papers reduced it to 0.07 
(Supplementary File 1 : Table S4, Model 1 with RDB); one of 
these was the study by Hsieh et al.24, whose “baseline” values 
were obtained 1 month after the treatment started. When we 
modeled the outcome instead of the baseline variances as the 
response, estimated heterogeneity (τ^=0.55) was almost doubled 
(Supplementary File 1 : Table S4, Model 6 with CDB). We found 
30 studies that compromised homoscedasticity: 11 (5.3%) with 
higher variance in the treated arm and 19 (9.1%), with lower 
variance (see heuristic method in Table 1). Based on the 
classical variance comparison tests (sensitivity analysis), 
these igures were slightly higher: 41 studies (19.7%) had 
statistically signiicant differences between outcome vari-
ances; 15 (7.2%) favored greater variance in the treated arm; and 
26 (12.5%) were in the opposite direction. Larger proportions 
were obtained from the comparisons over time of 95 treated 
arms: 16.8% had signiicantly greater variability at the end of 
the study and 23.2% at the beginning. Table 1 also summarizes 
those numbers for the F-test and paired Test.
Subgroup analyses suggest that signiicant interventions had 
an effect on reducing variability (Supplementary File 1 : 
Figures S5–S7), a fact which has already been observed in 
other studies25,26. Even more importantly, lower variances in 
the treated arm occur only in outcomes for which a positive 
response is deined as a decrease from baseline. This is in line 
with other works that have found a positive correlation between 
the effect size and its heteroscedasticity27,28. The fact is that it 
is dificult to ind heteroscedasticity when there is no overall 
treatment effect. The remaining subgroup analyses did not raise 
concerns (Section V in Supplementary File 1).
Discussion
Main findings
We aimed to show that comparing variances provides evidence 
about whether or not precision medicine is a sensible choice. 
When both arms have equal variances, then a simple and believ-
able interpretation is that the treatment effect is constant, which, 
if correct, would render futile any search for predictors of dif-
ferential response. This means that the average treatment 
effect can be seen as an individual treatment effect (not directly 
observable), which supports the use of a unique clinical guide-
line for all patients within the eligibility criteria, thus in turn 
also supporting the use of parallel controlled trials to guide 
decision-making in these circumstances. Otherwise, hetero-
scedasticity may suggest a need to specify further the eligibility 
criteria or search for an additive scale25,29. Because interaction 
analyses cannot include unknown variables, there might be value 
in repeating trials once any new potential interaction variable 
emerges (e.g., a new biomarker) as a candidate for a new sub-
group analysis. We have described how homoscedasticity can 
be assessed when reporting trials with numerical outcomes, 
regardless of whether every potential effect modiier is known.
We have provided a rough estimate of the proportion of inter-
ventions with different variability that might beneit from more 
precise medicine: Considering the most extreme result from 
Table 1 for comparison between arms, 1 out of 14 interventions 
(7.2%) had greater variance in the treated arm while 1 out 
of 8 interventions (12.5%) had lower variance. That is, we 
have found evidence of effect variation in only 1 out of 5 trials 
(40/208), suggesting a limited role for tailored interventions. 
These might be pursued by either a iner selection criteria 
(common effect within speciic subgroups), or with n-of-1 trials 
(no subgroups of patients with a common effect).
The sensitivity analysis of the change over time in the treated 
arm agreed with the indings in the comparison between arms, 
although this comparison is not protected by randomization. For 
example, the existence of eligibility criteria at baseline may have 
limited the initial variance (a hypertension trial might recruit 
patients with baseline SBP between 140 and 159 mm Hg), 
leading to the variance increasing naturally over time.
Regarding the subgroup analyses, we found that variability 
seems to decrease for treatments that perform signiicantly better 
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Figure 3. Funnel plots of variance ratio. Funnel plots of outcome variance ratio between arms (Panel A) and of outcome variance ratio over time (Panel B). The first shows all 208 
studies while the second shows only the 95 studies in which the variance of the difference between the baseline and final response was available. Vertical axis indicates precision for 
the comparison of variances; with points outside the triangle being statistically significant. Additionally, red points mark significant differences between the means, which correspond 
to each study’s objective to assess main treatment effects. In Panel A, points on the right indicate higher outcome variability for the treated individuals, as expected if there is patient-
by-treatment interaction; similarly, points on the left correspond to lower variability, although this is compatible with traditional Evidence-Based Medicine. Eleven (5.2%) out of 208 
studies reported exactly the same outcome variability in both arms. We observe more red points on the left, indicating that changes in the average accompany reductions in the 
variance. In Panel B, points on the right indicate higher variability in the treated arm at the end of the study, as expected in a scenario of heterogeneous treatment effect; points on 
the left correspond to lower variability at the end, which implies a more homogenous response after treatment. The largest number of points on the left side indicates a majority of 
experimental interventions that reduce variability. In addition, several of these interventions yielded significant results in the main endpoint. V
OT
: variance of the outcome in the treated 
arm. V
OC
: variance of the outcome in the control arm. V
BT
: variance of the outcome at baseline in the treated arm.
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than the reference; otherwise, it remains similar. Therefore, the 
treatment seems to be doing what medicine should do: hav-
ing larger effects in the most ill patients. Two considerations 
may be highlighted here: (1) as the outcome range becomes 
reduced, we may interpret that, following the intervention, this 
population is under additional control; but also, (2) as subjects 
are responding differently to treatment, this opens the way for 
not treating some (e.g., those subjects who are not very ill and 
thus lack the scope to respond very much), which subsequently 
incurs savings in side effects and costs.
This reduced variability could also be due to methodological 
reasons. One is that some measurements may have a “ceiling” 
or “loor” effect (e.g., in the extreme case, if a treatment heals 
someone, no further improvement is possible). In fact, according 
to the subgroup analysis of the studies with outcomes that indi-
cate the degree of disease (high values imply greater severity; 
e.g., pain), a greater variance (25%) is obtained in the treated 
arm (see Figure S5). However, in the studies with outcomes 
that measure the degree of healthiness (high values imply bet-
ter condition; e.g., mobility), the average variances match 
between arms, and this does not suggest a ceiling effect. As men-
tioned above, another reason might be that the treatment effect 
is not additive on the scale used for analysis, suggesting that it 
would be suitable to explore other metrics and transformations. 
For example, if the treatment acts proportionally rather than 
linearly, the logarithm of the outcome would be a better scale.
Limitations
There are three reasons why these indings do not invalidate 
precision medicine in all settings. First, there are studies where 
the variability in the response is glaringly different, indicating 
the presence of a non-constant effect. Second, the outcomes 
of some type of interventions such as surgeries, for example, 
are greatly inluenced by the skills and training of those admin-
istering the intervention; and these situations could have some 
effect on increasing variability. And, third, this study focuses 
on numerical endpoints; thus, time-to-event or categorical 
outcomes are out of scope.
The results rely on published articles, which raises some rel-
evant issues. First, some of our analyses are based on Normal-
ity assumptions that are unveriiable without access to raw 
data. Second, a high number of manuscripts (61.6%, Figure 2) 
act contrary to CONSORT30 advice in that they do not report 
variability. Thus, the included studies may not be representa-
tive. Third, trials are usually powered to test constant effects 
and thus the presence of greater variability would lead to an 
underpowered design; that is, if the control group variance is 
used to plan the trial, increased treatment group variance would 
reduce power (perhaps leading to non-publication). Fourth, the 
heterogeneity observed in the random-effects model may be the 
result of methodological inaccuracies23 arising from typographi-
cal errors in data translation, inadequate follow-up, insuficient 
reporting, or even data fabrication. On the other hand, this het-
erogeneity could also be the result of relevant undetected fac-
tors interacting with the treatment, which would indeed justify 
the suitability of precision medicine. A ifth limitation is that 
many clinical trials are not completely randomized. For exam-
ple, multicenter trials often use a permuted blocks method. 
This means that if variances are calculated as if the trial 
were completely randomized (which is standard practice), 
the standard simple theory covering the random variation of 
variances from arm to arm is at best approximately true25
The main limitation of our study arises from the fact that, although 
a constant effect always implies homoscedasticity on the cho-
sen scale, the reverse is not true; i.e., homoscedasticity does not 
Table 1. Variance comparison. Alternative possible methods for estimating the number and 
percentage of studies with different variances on comparisons between arms and over-time. 
Limits for declaring different variances come from different statistical methods: (1) the analysis 
relying on random-effects model and funnel plots; (2) the heuristic analysis based on number of 
studies that have to be deleted from the random-effects model in order to achieve a negligible 
heterogeneity (studies with larger discrepancies in variances were removed one by one until 
the estimated value of฀τ was as close as possible to that of the reference model – the one 
that compares the variances of the response at baseline. See Methods for details); (3) classic 
statistical tests for comparing variances (F for independent outcomes or Sachs’ test21 for related 
samples).¥ This comparison was performed on studies reporting enough information to obtain 
the variability of the change from baseline to outcome, for example because they provide the 
correlation between outcome and baseline values.
Comparing 
variances











14(6.7%) 26 (12.5%) 168(80.8%)
Heuristic 11 (5.3%) 19 (9.1%) 178 (85.6%)
F-test 15 (7.2%) 26 (12.5%) 167 (80.3%)
Outcome versus 
baseline in treated 
arm
95 ¥ Random-effects 
model
16 (16.8%) 22(23.2%) 57(60.0%)
Heuristic 13 (13.7%) 19 (20.0%) 63 (66.3%)
Paired test 16 (16.8%) 22 (23.2%) 57 (60.0%)
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necessarily imply a constant effect. For example, the highly 
speciic and non-parsimonious situation relected in Figure 4 
indicates homoscedasticity but without a constant effect. Nev-
ertheless, a constant effect is the simplest explanation for homo-
scedasticity (Section VIII of Supplementary File 1: Conditions 
for homoscedasticity to hold without a constant effect under 
an additive model).
Conclusion
In summary, for most trials, the variability of the response to 
treatment scarcely changes or even decreases. Thus, if we take 
into account the limitation previously explained in Figure 4, 
this suggests that the scope of precision medicine may be less 
than what is commonly assumed. Evidence-Based Medicine 
(EBM) operates under the paradigm of a constant effect assump-
tion, by which we learn from previous patients in order to 
develop practical clinical guidelines for future treatments. Here, 
we have provided empirical insights to postulate that such a 
premise is reasonable in most published parallel randomized 
controlled trials. However, even where one common effect applies 
to all patients fulilling the eligibility criteria, this does not imply 
that the same decision is optimal for all patients. More spe-
ciically, this is because different patients and stakeholders may 
vary in their weighting not only of eficacy outcomes, but also 
of the harm and cost of the interventions – thus bridging the gap 
between common evidence and personalized decisions.
Our results uphold the assertion by Horwitz et al. that there 
is a “need to measure a greater range of features to determine 
[...] the response to treatment”31. One of these features is an old 
friend of statisticians, the variance. Looking only at averages 
can cause us to miss out on important information.
Data availability
Data is available through two sources:
•    A shiny app that allows the user to interact with the data 
without downloading it: http://shiny-eio.upc.edu/pubs/
F1000_precision_medicine/
•    The Figshare repository: https://doi.org/10.6084/
m9.igshare.555265618
In both sources, the data can be downloaded under a Creative 
Commons License v. 4.0.
The code for the main analysis is available at the following 
link: https://doi.org/10.5281/zenodo.123953922
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Figure 4. Scenario representing a fictional trial with 8 participants 
and having homoscedasticity but a non-constant effect. SBP 
potential values of each patient in both groups (C: control; T: 
treated) under a highly hypothetical scenario: the treatment effect 
has no value if systematically applied to the whole population; but if 
n-of-1 trials could be performed in this situation, the best treatment 
strategy would be chosen for each patient and the overall health of 
the population would be improved.
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Supplementary File 1: The supplementary material contains the following sections
Click here to access the data
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- Section I: Constant effect assumption in sample size rationale
- Section II: Bibliographic review
- Section III: Descriptive measures
- Section IV: Random-effects models
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) in independent samples




) in paired samples
- Section VIII: Conditions for homoscedasticity to hold without a constant effect under an additive model
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We are grateful to Professor Dennis Lendrem for his review and for his commentsゴ which
positively evaluate our articleズ Indeedゴ the message that we want to highlight in our work
is that precision medicine can be useful under certain circumstancesゴ but there is still ┑a
medicineゴ and researchers must take into account that the studylot of┒ room for プgenericベ 
of variability in their data provides valuable information to all of societyズ
Have the authors shown that the comparison of variances is a useful but not definitive tool for
assessing whether or not the assumption of a constant effect holdsバ  I think they haveズ
Thank youズ We have shown some prudence in this statement because we know that there
Page ÷≠ of ＞∴
F÷×××Research ＝×÷∴ゴ ≧ジ≠× Last updatedジ ÷＝ JUN ＝×÷∴
 
÷ズ  
Thank youズ We have shown some prudence in this statement because we know that there
may be other techniques to evaluate the presence of a constant effectゴ such as the one
proposed by Caughey et alズ ┕÷┖
Caughey Dゴ Dafoe Aゴ Miratix Lズ Beyond the sharp nullジ permutation tests actually
test heterogeneous effectsズ Summer meeting of the Society for Political









Thank youズ We completely agreeズ Our work focuses on a narrow spectrum of studies with
a specific design ┑parallel randomized controlled trials┒ and with a numerical outcomeズ In
additionゴ the lack of information in many studies due to poor reporting may suggest that
the sample is not completely representativeズ For these reasonsゴ we believe that more
 studies should be conducted around this topicズ
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Many thanks for your comments that will help us to clarify our paperズ
Yesゴ we have concentrated on the analysis of variabilityズ As we show ┑eズgズゴ figures ÷ゴ
panels A and B┒ a constant effect of the intervention allows stakeholders to provide
unique advice to patients within the eligibility criteriaズ And also ┑＝  paragraph of the
introduction┒ゴ a constant effect implies equal variances among the treatment groupsズ Soゴ
our aim was to show readers that the comparison of variances could be a useful way to
provide information about the need to further personalize the clinical adviceズ
In our article we deal with heteroscedasticity and heterogeneityズ The former is the main
objective of the study and it refers to the presence of different variances in the two
treatment armsズ The measure we used to quantify it was the ratio of variances between
armsズ The heterogeneityゴ howeverゴ refers to how this measure oscillates between the
different included studiesズ The measure to assess it was the tau／＝ statistic obtained from
the randomゾeffects modelズ As this referee points outゴ the high heterogeneity in the
variance ratio across the studies indicates that we cannot establish a single conclusion
for every single studyズ Our results highlight that heteroscedasticity is negligible in most of
the published parallel trials with numerical outcomeゴ and thusゴ precision medicine would
seem unjustifiedズ
As we argue in the discussion sectionゴ we do not want to end precision medicineザ we
simply advocate the rational use of it while assessing the costs and benefits of its
implementation in each specific situationズ
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Thanks for the appraisementズ Yesゴ you are rightザ surelyゴ this is not the definitive argument
against precision medicineゴ but we believe it is a wellゾfounded method ┑variance
comparison┒ that every researcher could easily apply in their studies for assessing the
constant effect assumptionズ We just want to emphasize thatゴ in any senseゴ we have to
develop and use methods to observe the convenience for precision medicineズ As we
mentioned in the previous pointゴ we warn against abuse when there is no evidence that
the treatment effect varies among patientsズ
Alsoゴ the writing is fairly poorゴ which is surprisingゴ since Drズ Senn is one of the best writers I have
ever had the pleasure of readingズ
Of courseゴ we share your opinion about Stephen Sennとs writing skillsズ The three main
authors ┑JCゴ JAG and EC┒ are not native English speakersズ We have worked closely with
Matthew Elmoreゴ an author working both as English editor and patient representativeズ As
a result of your commentゴ in this latest version we have done our best to really improve
the readability of the manuscript and we have completely restructured the Discussion
section to clarify the messageズ 
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We have read this submissionズ We believe that we have an appropriate level of expertise to







We are grateful to Professor Richard Stevens and Professor David Nunan for their
commentsゴ which helped us to clarify┄improve our manuscriptズ





Thatブs rightズ The correct message is exactly thatジ there is not enough evidence for wide
use of personalized medicineゴ but some sentences still remained impreciseズ We are






Thank youズ We tried to clarify this issue in response to Prof Whiteズ Howeverゴ we want to
emphasize that this sentence came from an answer to the refereeザ but it has never been
included in the manuscriptズ
Anywayゴ in this new versionゴ we have replaced the term どneedど in almost every sentence
where it appeared ┑÷ of them in the Abstract┒ for other expressions in order to ease the
messageズ
Prof White is also correct to challenge the remark on page ∴ that とthe simplest interpretation ズズズ thus
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Thank you for this important insightズ Firstゴ we have tried to soften the tone of the phrase
by changing どthe simplest interpretationど to どa simple and believable interpretationどズ
Secondゴ we have reworded the last part of the sentence according to the reviewersブ
suggestionジ
プゼtreatment effect is constantゴ whichゴ if correctゴ would render futile any search for
predictors of differential responseベ
With these wording improvementsゴ we have decided to move this sentences to the






ズ Thank you for your suggestion We refer to merely descriptive resultsズ Howeverゴ to avoid
ambiguitiesゴ we have rewritten the Abstract and the Results sectionジ
Previous Abstractジ We found that the outcome variance was more often smaller in the
intervention groupゴゼ
Current Abstractジ The mean variance ratio is significantly lower than ＞ and the lower
variance was found more often in the intervention group than in the control groupゴ
suggesting it is more usual for treated patients to be stableズ
Previous Resultsジ On averageゴ the outcome variance ratio is close to oneゴ with evidence of
smaller variability in the treated armズ
Current Resultsジ The mean variance ratio is significantly lower than ＞ and the lower
variance was found more often in the intervention group than in the control groupズ
Methods ゾ regarding the target populationゴ it could be made more clear that とquantitative outcomesと
refers to outcomes with continuous dataズ
Thank you for the commentズ  In factゴ our work includes both studies with continuous and
discrete outcomes ┑eズgズゴ scales┒ズ For this reasonゴ we have changed the term どquantitativeど





Thank you for this pointズ On the one handゴ nowゴ we have introduced Figure ≠ earlier and
we have included some sentences to explain itズ On the other handゴ we have repeated the
citation of Table ÷ in several places in order to clarify the source of each percentage
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Thank you for your commentズ We have rewritten the percentages in Figure ＝ according to








We agree that the interpretation is overemphasized according to the findings of our workズ
We have tried to improve both sentencesジ
Previous sentenceジ ゼthus in turn also supporting evidenceゾbased medicine
Current sentenceジ ゼthus in turn also supporting the use of parallel controlled trials to
guide decisionゾmaking in these circumstancesズ
Previous sentenceジ Hereゴ we have provided empirical insights for the rationale behind
EvidenceゾBased Medicineズ
Current sentenceジ Hereゴ we have provided empirical insights to postulate that such a
 premise is reasonable in most published parallel clinical trialsズ
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We are thankful for the comments from Profズ Ian Whiteゴ which have helped us greatly in
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We agree that Holland is using the concept of Average Causal Effect ┑ACE┒ザ howeverゴ he
also mentions that どThe assumption of constant effect makes the value of the average
causal effect relevant to every unitゴ and thereforeゴ allows T to be used to draw causal
どズ Howeverゴ we wonder to whom this quote is relevantジ toinferences at the unit level 
health managersバザ or to doctors giving specific advice to individual patientsバ In any caseゴ
our statement will still remain validジ health managers would like to know the amount of
variability added by the treatmentザ orゴ even betterゴ they would like to know any additional












Thank you for this observationザ howeverゴ we disagreeズ While it is certainly true that
science currently cannot provide this informationザ that does not mean that we donブt need
this information in order to provide individualized adviceズ For usゴ プneedベ is the correct
wordズ Perhaps our disagreement is simply a question of nuanceゴ for exampleゴ maybe Profズ






Thank youゴ although we disagreeズ As stated beforeジ maybe some patients may rely on an
average treatmentズ Howeverゴ the best clinicians would like to know the effect on both
subgroupsジ this is why we プneedベ to know the プdistributionベ of the effect size among the
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Thank youゴ although we still disagree with Profズ Ian Whiteブs interpretationズ 
If the constant effect assumption does not holdゴ new paradoxes may appearズ For exampleゴ
we agree that a different effect in some units may justify a tailored recommendationズ
Howeverゴ in the case of a reduced variance with a similar mean ┑as in panel Eゴ Figure ÷┒ゴ
more patients would finish within reference or プnormalityベ valuesゴ which may be




 Againゴ thank youゴ although we disagreeズ As a constant ┑ ┒ is independent of anyeffect
















Thank youズ We have clarified this issue adding this sentence before the formulasズ
プThusゴ the withinゾstudy variance was estimated using the following formulasジベ
In Table ÷ゴ プRandom modelベ is an inadequate description of the complex procedure described in
the captionズ
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the captionズ
Thank youズ As a consequence of your suggestionsゴ we have decided to expand the table
by specifying the ≠ performed analyses based onジ ÷┒ the random effects modelザ ＝┒ the
heuristic method of eliminating oneゾtoゾone studies ┑what we previously called どrandom








Thank youズ We are happy Prof White thinks it プprovides useful insightsベ and that he likes
that it should プremain availableベズ As we interpret his commentsゴ he appears to believe that
the paper is now a worthwhile contribution to scienceズ Anywayゴ we wonder if a






It seems to us that we agree more than we disagree with Profズ Ian Whiteズ  We agree that
the assumption of a constant effect is as unrealistic as some statements from the Normal
GaussゾLaplace distributionズ Howeverゴ the constant effect has nevertheless served as a
useful assumption for facilitating medical and social decisions arrived at on the basis of
evidenceゾbased medicineズ The relevant question is not whether or not the assumption is
trueゴ but how much the effects deviate from a constant modelズ This is the point of our
proposalゴ namely that it is necessary to quantify how much variability is added by the
treatmentズ 
In any caseゴ we would like to thank again Profズ Ian Whiteズ Despite having different
interpretationsゴ he has helped us to significantly improve the articleズ 
 No competing interests were disclosedズCompeting Interestsジ
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Is the work clearly and accurately presented and does it cite the current literatureバ
No
Is the study design appropriate and is the work technically soundバ
No
Are sufficient details of methods and analysis provided to allow replication by othersバ
No
If applicableゴ is the statistical analysis and its interpretation appropriateバ
No
Are all the source data underlying the results available to ensure full reproducibilityバ
No




I have read this submissionズ I believe that I have an appropriate level of expertise to state that I
do not consider it to be of an acceptable scientific standardゴ for reasons outlined aboveズ
Author Response ×≦ Nov ＝×÷∞
ゴ Universitat Politècnica de Catalunyaゴ Barcelonaゴ SpainJordi Cortés
We are sincerely thankful for the critical review from Profズ Saskia le Cessieズ Nextゴ we will
try to clarify the raised issuesズ
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As this question deals with the same issue posed by Professor Ian Whiteゴ we use more or
less the same answerジ
Paul Holland ┕÷┖ゴ in his paper about statistics and causal inferenceゴ statedジ プThe
assumption of constant effect is that the effect of t on every unit is the same ┕ゼ┖ズ ┕It┖
ベ makes the value of the average causal effect relevant to every unitズ
Without this assumptionゴ the value of the プaverage causal effectベ is not enough to convey
all the information about the treatment effectズ If the effect randomly varies among the
different units ┑as shown in panel D of Figure ÷┒ゴ we need to characterize its distributionジ
for exampleゴ by means of a normal distribution with its mean ┑delta┒ and standard
deviation ┑SD┒ズ Depending on the value of this SDゴ we may consider applying the
intervention to the full population or notズ In the case of an interaction with measurable
baseline characteristics ┑as shown in panel C of Figure ÷┒ゴ we need to specify the different
delta values for each groupズ
Without specification of the further parameters required to characterize a nonゾconstant
effectゴ the reader cannot distinguish whetherジ ┑a┒ the authors were looking for a
nonゾconstant effectゴ but they erroneously omitted those further details required to specify
this sophisticated effectザ or ┑b┒ they were just assuming a constant effect ┑perhaps
unconsciously┒ズ We agree with Profズ White that authors should be fully transparent about
those assumptionsザ and with Grissom and Kim ┕＝┖ in the sense that those further
sophisticated situations may require a broader approach than just looking at the meansズ 
┕÷┖ HOLLANDゴ P ﾍ PAULゴ Wズ ┑÷∴∞≦┒ズ Statistics and Causal Inferenceズ Journal of the
American Statistical Associationゴ ∞÷┑≠∴≦┒ゴ ∴＜＞ゾ∴≦×ズ
┕＝┖ GRISSOMゴ Rズ Jズ ﾍ KIMゴ Jズ Jズ ┑＝××＞┒ズ Effect Sizes for Researchジ a Broad Practical





You are rightズ Although we have extensively explained it in sections VI and VII of the
supplementary materialゴ we have clarified it in a new version of the manuscriptジ
Beforeジ プAs there is only one available measure for each studyゴ both sources of variability
cannot be empirically differentiatedジ ┑i┒ within study or random or that one related to
sample sizeザ and ┑ii┒ heterogeneityズ In order to isolate the secondゴ the first was
theoretically estimated using the Delta method ┆as explained in Sections V and VI in
Supplementary File ÷ズベ
Afterジ プAs there is only one available measure for each studyゴ both sources of variability
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Afterジ プAs there is only one available measure for each studyゴ both sources of variability
cannot be empirically differentiatedジ ┑i┒ within study or random variabilityザ and ┑ii┒
heterogeneityズ To isolate the secondゴ the first was estimated theoretically using either the
Delta method in the case of comparison betweenゾarm or using some approximation in the
case of comparison over time ┑see details in Sections VI and VII of Supplementary File ÷┒ジ
  V┕log┑VたOT┄VたOC ┒┖３＝┄┑nたOTゾ＝┒¶＝┄┑nたOCゾ＝┒      ┑between arms┒




Thanksズ We have corrected itズ
 
＜ズ The definition of I／＝ is not clearゴ  it is unclear what nu／＝ isズ
Thank you for the suggestionズ Regarding the definition of I／＝ゴ we have added a new
reference ┕÷┖ that contains a broader explanation of its meaningズ Regarding nu／＝ゴ we have
removed the second definition ┑プthe expected value of the error varianceベ┒ゴ since it had
already been previously definedズ





In factゴ although we define the measure of I／＝ゴ our explanations always underlie the
interpretation of tauズ
The question about why we do not use the prediction intervals is very appropriateズ This
was our initial ideaゴ but Carlisleとs paper ┕÷┖ made us think that there could be some
methodological deficiencies in the random assignments that involve artificially different
variances between armsズ Howeverゴ after making the decisionゴ we found that the number of
studies with statistically different variances using our どheuristicど method or using the
prediction intervals was very similarズ This can be checked by comparing the results
shown in Table ÷ with the points outside the triangle in Figure ≠ズ
┕÷┖ Carlisle JBジ Data fabrication and other reasons for nonゾrandom sampling in ＞×∞≧
randomisedゴ controlled trials in anaesthetic and general medical journalsズ Anaesthesiaズ
＝×÷≧ザ≧＝┑∞┒ジ∴＜＜┆∴＞＝ズ ＝∞＞∞×≦＞÷ ÷×ズ÷÷÷÷┄anaeズ÷≠∴≠∞
≦ズ It is unclear how the model to assess homoscedasticity over time is formulatedズ
The methodology is explained in Section IV of the supplementary fileズ As the methodology
was relatively similar to the comparison between groupsゴ we decided to omit the details in
the statistical analysis section so as not to wear down the readerズ
≧ズ In the heading of Table ÷ it is now explained how the distinction between increased variabilityゴ
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Thank you for your adviceズ We have introduced two modificationsズ
Firstゴ just to clarifyゴ we have added an additional introductory paragraph in the statistical
analysis section mentioning the ＝ methods before explaining themジ
To compare the variancesゴ two different methods have been usedジ one based on a
randomゾeffects model and the other based on classical variance comparison testsズ
Secondゴ it is our opinion that doubts arise in regard to how the randomゾeffects model
determines which studies have significantly different variances ┑since we believe it is
obvious with variance comparison tests┒ゴ therefore we have added the following
explanatory text in the statistical analysis sectionジ
Specificallyゴ studies with more extreme outcomes were removed one by one until
achieving an estimated value of 】 similar to the one obtained from the reference modelズ
These deleted studies were considered to be those that had significantly different









The term どmaskedど refered to the fact that this analysis was defined without looking at the
data previouslyズ To clarifyゴ we have changed どmasked specifiedど to どpreゾspecifiedどズ We
agree that the method which obtains the studies with significantly different variances is
heuristicズ Howeverゴ it provides almost the same number of significant studies as when
using the limits defined by the funnelゾplots in Figure ≠ズ
The reference model is the one in which the variances of the two groups are compared at
the baselineジ It is the first model of Table S＜ of the supplementary fileズ To clarifyゴ we have
added an additional sentence in the legend of Table ÷ジ 
プReference model ┆ the one that compares the variances of the response at baselineベズ
Alsoゴ we have slightly modified the explanation of this heuristic method to clear up
doubtsジ 
Beforeジ プstudies with more extreme outcomes were removed one by one until achieving
an estimated value of tau similar to the one obtained from the reference modelズベ 
Afterジ プstudies with larger discrepancies in variances were removed one by one until the






You are right in all the matters you mentionズ
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You are right in all the matters you mentionズ
Baseline heterogeneity refers to the model that uses the logarithm of the baseline
variances ratio as responseズ 
In the new version of the manuscriptゴ we have clarified that when we say that
プheterogeneity is approximately doubledベゴ we refer to the estimated tauズ
Beforeジ プHeterogeneity was approximately doubledズベ
Afterジ プEstimated heterogeneity ┑hatたtau┒ was approximately doubledズベ
Alsoゴ instead of using the term どsensitivity analysisどゴ which is not very specificゴ we now
specifically mention what analysis we are referring toズ
Beforeジ プThese figures were slightly higher in the sensitive analysisズベ








We have modified the legend of Figure ≠ズ
Beforeジ プVたBTジ Variance of the Outcome at baseline in the Treated armベズ
Afterジ プVたBTジ Variance at Baseline in the Treated armベズ
In the rest of the documentゴ we think that there is no ambiguity in the use of the term





It is not our intention in this statement to make an equivalence between
heteroscedasticity and personalized medicineゴ iズeズジ
Heteroscedasticity ４ゾ５ Precision medicine
With the use of a conditional in the sentenceゴ we want to highlight that the studies where
personalized medicine has more room are those in which different variability has been
observed andゴ thereforeゴ they are those of which we are sure that the effect of the
treatment is not constantジ






We wanted to emphasize that a treatment that is not effective because it does not modify
the mean of the outcome could be beneficial by decreasing the varianceゴ since this
implies that there is a greater number of patients within the reference range ┑we have
changed the terminology プnormality rangeベ to プreference rangeベ in order to avoid
ambiguities┒ズ We have changed the text in the following wayジ
Beforeジ プProvided there are no differences in meansゴ the latter implies a larger proportion
of プcuredベ patients within the normality rangeズベ
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of プcuredベ patients within the normality rangeズベ
Afterジ プEven if there are no differences in meansゴ lower variance implies a larger






Thank youズ We have tried clarified this sentenceズ
Beforeジ プFirstゴ the heterogeneity found in our analysis indicates that the observed lower
variability in the experimental arm cannot be extrapolated to all individual studiesズベ
Afterジ プFirstゴ there are studies where the variability in the response is glaringly differentゴ
indicating the presence of a nonゾconstant effectズベ
 
We sincerely thank the referee for the time devoted to her commentsゴ because despite not
having considered the manuscript acceptableゴ she has helped us to considerably improve
 the manuscriptズ 
 No competing interests were disclosedズCompeting Interestsジ
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Is the work clearly and accurately presented and does it cite the current literatureバ
No
Is the study design appropriate and is the work technically soundバ
No
Are sufficient details of methods and analysis provided to allow replication by othersバ
No
If applicableゴ is the statistical analysis and its interpretation appropriateバ
No
Are all the source data underlying the results available to ensure full reproducibilityバ
No
Are the conclusions drawn adequately supported by the resultsバ
No
 No competing interests were disclosedズCompeting Interestsジ
I have read this submissionズ I believe that I have an appropriate level of expertise to state that I
do not consider it to be of an acceptable scientific standardゴ for reasons outlined aboveズ
Author Response ＝≦ Jul ＝×÷∞
ゴ Universitat Politècnica de Catalunyaゴ Barcelonaゴ SpainJordi Cortés
We are honestly thankful for the critical review from Profズ Ian Whiteゴ especially for
highlighting the discrepancies between his and our interpretation regarding the average
treatment effect ┑ATE┒ and the constant effectズ
Neverthelessゴ we have the deep conviction thatゴ by some honest mistakeゴ Profズ White did
not see our separate responses to each reviewerズ Based on his comment that we did not
answer Erica Moodieゴ which we had done as well as some other commentsズ 




Page ≠≠ of ＞∴











Paul Holland ┕÷┖ゴ in his paper about statistics and causal inferenceゴ statedジ プThe
assumption of constant effect is that the effect of t on every unit is the same ┑ゼ┒ズ ┑It┒
ベmakes the value of the average causal effect relevant to every unitズ
Without this assumptionゴ the value of the プaverage causal effectベ is not enough to convey
all the information about the treatment effectズ If the effect randomly varies among the
different units ┑as shown in panel D of Figure ÷┒ゴ we need to characterize its distributionジ
for exampleゴ by a normal distribution with its mean ┑delta┒ and standard deviation ┑SD┒ズ
Depending on the value of this SDゴ we may consider applying the intervention to the full
population or notズ In the case of an interaction with measurable baseline characteristics
┑as shown in panel C of Figure ÷┒ゴ we need to specify the different delta values for each
groupズ
Without specification of the further parameters required to characterize a nonゾconstant
effectゴ the reader cannot differentiate betweenジ ┑a┒ the authors were looking for a
nonゾconstant effectゴ but they erroneously omitted those further details required to specify
this sophisticated effectザ or ┑b┒ they were just assuming a constant effect ┑perhaps
subconsciously┒ズ We agree with Profズ White that authors should be fully transparent about
those assumptionsザ and with Grissom and Kim ┕＝┖ in the sense that those further
sophisticated situations may require a broader approach than just looking at the meansズ 
┕÷┖ HOLLANDゴ P ﾍ PAULゴ Wズ ┑÷∴∞≦┒ズ Statistics and Causal Inferenceズ Journal of the
American Statistical Associationゴ ∞÷┑≠∴≦┒ゴ ∴＜＞ゾ∴≦×ズ
┕＝┖ GRISSOMゴ Rズ Jズ ﾍ KIMゴ Jズ Jズ ┑＝××＞┒ズ Effect Sizes for Researchジ a Broad Practical






This is the essential criticismズ It was raised ┑and answered┒ in points ÷ to ≠ of the previous
review from Prof Whiteズ We have added a new section to the supplementary file ÷ ┑
Conditions for homoscedasticity to hold without a constant effect under an additive model
┒ showing the conditions required for V┕Y┑÷┒┖３V┕Y┑×┒┖ under the additive modelズ
Essentiallyゴ if the effect was randomゴ we need the correlation between the effect and
V┕Y┑×┒┖ to be exactlyジ 
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V┕Y┑×┒┖ to be exactlyジ 
ゾ ‰ ┝ Sigmaたeffect┄SigmaたY┑×┒ズ
In the Discussion section of the ＝  version of the paperゴ we did already include an
extended explanationジ
プOur second objective was ┑ズズズ┒ the remaining ∞×† of the studies agrees with the design
assumption of a constant effectズベ
≠ズ The reportingゴ though much improvedゴ is still unclear in some waysズ For exampleゴ
a┒ what is the プbaseline heterogeneity ┑】＝┒ベ that is estimated as ×ズ≠÷ ┑p≦┒バ
This was previously raised by Profズ Ian White in the first revision ┑プMethodsゴ point ＝ベ┒ゴ
which offered us the opportunity to improve our presentation ┑see our previous answer┒ズ 
It is an estimate of the variability of the logarithm of the ratio of variances at baselineズ All
the models are specified in the legend of Table S＜ in Supplementary File ÷ズ
Randomization should lead to this tau／＝ being close to ×ザ andゴ in factゴ by removing only
the ＜ most extreme studies reduces tau from ×ズ≠÷ to ×ズ×≧ゴ indicating that these ＜ studies
have some problemsゴ such as in one study using outcomes that were obtained ÷ month
after the start of treatment as the baseline values ┕≠┖ズ
┕≠┖ Hsieh LLゴ Kuo CHゴ Yen MFゴ et alズジ A randomized controlled clinical trial for low back
pain treated by acupressure and physical therapyズ Prev Medズ ＝××＜ザ ≠∴┑÷┒ジ ÷≦∞┆≧≦
b┒ what does this meanジ プboth sources of variability cannot be empirically differentiatedジ ┑i┒ within
study or random or that one related to sample sizeザ and ┑ii┒ heterogeneityベバ
The model can be defined without using scientific notationジ
      Response ３ Mean ¶ Interゾstudy variability ¶ Intraゾstudy variability
By having a single measure per studyゴ we do not have enough information to distinguish
between intraゾstudy variability and interゾstudy variability of the measure of interestズ For
this reasonゴ the delta method was used to estimate the first and distinguish between
themズ
c┒ Table ÷ remains unclear to meズ
┕See also our previous answer to Saskia Le Cessie comment ÷÷ズ┖
The white rows in Table ÷ are the direct result obtained from a statistical test for
comparing the variances between groups ┑F test┒ or beforeゾafter ┑paired test┒ in the
experimental armsズ From hereゴ the studies are divided into not significant or significant in
one or the other directionズ
nd
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In the gray rowsゴ  the significant studies are those that should be removed in order to
obtain a heterogeneity as close as possible to the baseline ┑which supposedly should be
zero by randomization┒ズ All those details were explained in either the text or the legend
labelsズ
I am also disappointed that the authors have not replied to Erica Moodieブs critical commentsズ
Our reply to Erica Moodie was published on the F÷××× website at the same time as the
other twoズ We gave our best efforts in responding to her commentsズ We are grateful for
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Is the work clearly and accurately presented and does it cite the current literatureバ
Yes
Is the study design appropriate and is the work technically soundバ
Yes
Are sufficient details of methods and analysis provided to allow replication by othersバ
Yes
If applicableゴ is the statistical analysis and its interpretation appropriateバ
No
Are all the source data underlying the results available to ensure full reproducibilityバ
Yes




I have read this submissionズ I believe that I have an appropriate level of expertise to confirm that




JOINT ANSWER to Ian White and Saskia le Cessie
This is a general response to Ian White and Saskia Le Cessie on why we stated that the
standard clinical trial design and analysis assume a constant effectズ
In the followingゴ ┑÷┒ we update the standard sample size rationaleザ and ┑＝┒ we explain why
inflated variances may require precision medicine in just two general casesジ ┑a┒
interactionゴ as represented in Figズ ÷ゴ panel Cザ and ┑b┒ random treatment effectゴ Figズ ÷ゴ
panel Dズ
Under the NeymanゾPearson framework to determine sample sizeゴ a single effect
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Under the NeymanゾPearson framework to determine sample sizeゴ a single effect
size value ┥ is specified under the alternative hypothesis H÷ゴ assuming in that way
a constant effectゴ as in Figズ ÷ゴ panels A ┑H×┒ and B ┑H÷┒ズ
We devise two situations thatゴ because they result in higher varianceゴ they would
need personalized medicineジ
Interaction between treatment and a baseline variable such usゴ for exampleゴ
gender ┑Figズ ÷ゴ panel C┒ズ In this scenario there are two subpopulations ┑eズgズゴ
men and women┒ with different treatment effects that require the effect to be
made further プpreciseベズ
Random treatment effect on each patient ┑Figズ ÷ゴ panel D┒ズ In this scenarioゴ
the effect size does not depend on a known patient baseline characteristic
and the only way to estimate the individual patient effect is by means of
individualized trials ┑プn of ÷ベ trials┒ズ
 
Those ＝ hypothetical scenariosゴ lead to an increased varianceズ Converselyゴ scenarios E
and F represent two similar situations ┑interaction and random effect┒ but result in
reduced variance ┆without relevant changes on the averageズ Although we agree that in
those two last scenarios leading to reduced variability the specific patient treatment effect
may still be unknown because the outcome has reduced variability with a similar central
overall positionゴ we argue that patients in those situations were subject to プfurther
controlベ ┑having more stable values within the boundaries of プnormalityベ┒ズ 
Soゴ the usual sample size rationale specified by statisticians in trials assumes a constantゴ
unique effect that agrees with the clinical and legal interpretation that the effect is the
same ┆ or at least similar enough to be considered homogeneous ┆ for all the patients
fulfilling the eligibility criteriaズ
To illustrate this secondary プargumentベゴ we reviewed the sample size rationale for the last
┑at that time┒ ÷× protocols published in Trialsゴ and we found that all of them defined a
single effect size ┑÷××†ゴ twoゾsided ∴＞† confidence interval from ≦∴† to ÷××†┒ズ In
additionゴ we have included a new column in Table S÷ with the main analysis showing that
the SAP in all those cases ┑÷× out of ÷×ゴ ∴＞†CI from ≦∴ to ÷××†┒ was also designed to
estimate a singleゴ constant effectズ
We have modified Figズ ÷ ┑panels E and F┒ to show decreasing variance treatment effectsゴ
but now without affecting the averageズ We have also improved the ＝ following sentencesジ
Before ┕Abstract┖ジ Howeverゴ the conventional design of randomized trials assumes that
each individual benefits by the same amountズ
After ┕Abstract┖ジ Howeverゴ conventional clinical trials are designed to find differences with
the implicit assumption that the effect is the same in all patients within the eligibility
criteriaズ
Before ┕Introduction┖ジ The assumption that the average effect equals the single unit effect
underlies the rationale behind the usual sample size calculationゴ where only a single
effect is specifiedズ As an exampleゴ the ÷× clinical trials published in the Trials Journal in
October ＝×÷≧ ┑see Supplementary materialジ Table S÷┒ were designed under this scenario
of a fixedゴ constant or unique effect in the sample size calculationズ
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After ┕Introduction┖ジ The assumption of homoscedasticity in the usual calculations of
sample size is better interpreted under the constant effect model ┑Figure ÷ゴ panels Aゴ H ザ
and Bゴ H ┒ズ As an exampleゴ the ÷× clinical trials published in the Trials Journal in October
＝×÷≧ ┑Table S÷ of Supplementary material┒ were designed with only a constant for the
effect sizeズ Furthermoreゴ all their analyses were designed to test ┑and estimate┒ a single
constant for the effect sizeズ In other wordsゴ there was mention of neither any possible
interaction with baseline variables ┑Figure ÷ゴ scenarios C and E┒ゴ nor of any random
variability for the treatment effect ┑Figure ÷ゴ scenarios D and F┒ザ and thusゴ all those trials
were designed to test a constant effectズ
We have also updated the legend of Figure ÷ to highlight that now panels C to F show only
possible individual treatment effects on variances but not on meansズ
We are deeply grateful to Ian White and Saskia le Cessie for highlighting the need to
clarify this crucial issueズ
Saskia le Cessie










We are grateful to Profズ Saskia le Cessie for her suggestionsゴ which definitively help us to









Yesゴ our impression is that at least some trialists are not aware of these assumptionsズ But
the fact that we wanted to highlight is that trials are usually designed to provide evidence
for just one parameter ┑in our context the プeffect sizeベ collected by the difference of
means┒ without further specificationゴ neither in the sample size rationale nor in the
analysis of the further parameters required by precision medicineズ We have addressed
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＝ズ Introductionズ I liked Figure ÷ with the different explanationsズ









Thanksズ We fully agree that discussion was introduced too lateゴ and we have further
clarified it in the Methods section and in the flow chartズ The modifications are described
belowズ
Before ┕Methods┖ジ Our target population was parallel randomized clinical trials with
quantitative outcomes
After ┕Methods┖ジ Our target population was parallel randomized clinical trials with
quantitative outcomes ┑not including timeゾtoゾevent studies┒
Before ┕Flow chart┖ジ Qualitative outcome







Thanksズ The model includes the ┑logarithm of the┒ baseline variances ratio because some
imbalances in the initial variability between groups ┑after randomization┒ can occur simply
by chanceズ It is foreseeable that these baseline differences in variability may influence the
final differences in variabilityズ This baseline logゾratio was highly significant ┑p ４ ×ズ×××÷┒ in
the modelズ 
All your suggestions related to the statistical analysis ┑＜ゴ ≧ゴ ∞ゴ ∴ and ÷÷┒ and the random
effects model have been addressed through a clearer and longer explanation of the model
in the statistical analysis section ┑detailed here and in the manuscript┒
Neverthelessゴ we provide the following rule of thumb for interpreting the parameters ]
┑heteroscedasticity┒ and I  ┑heterogeneity┒ of the randomゾeffects modelズ
mu ４ × ゾゾ５     On averageゴ studies have lower variability in the experimental armズ
＝
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÷ズ  
mu ４ × ゾゾ５     On averageゴ studies have lower variability in the experimental armズ
mu ５ × ゾゾ５     On averageゴ studies have greater variability in the experimental armズ
 
I／＝ ４ ＝＞† ゾゾ５ As the point estimate of heterogeneity is not high enoughゴ mu is constant
throughout all the studiesズ
I／＝ ４ ＝＞† ゾゾ５ As the point estimate of heterogeneity is highゴ mu does not apply to every
single studyズ
 
mu ４ × ﾍ I／＝ ４ ＝＞† ゾゾ５  Not one study requires precision medicineズ
mu ４ × ﾍ I／＝ ５ ＝＞† ゾゾ５  Some studies require precision medicineズ
mu ５ × ﾍ I／＝ ４ ＝＞† ゾゾ５  All studies require precision medicineズ
mu ５ × ﾍ I／＝ ５ ＝＞† ゾゾ５  Most studies require precision medicineズ
┕The threshold of ＝＞† for I／＝ is based on PRISMA Statement ┕÷┖ that considers values
under this cutpoint as lowズ┖
The estimates of these parameters in our data were mu ３ ゾ×ズ÷＝ and I／＝ ３ ∞×ズ∞†ゴ which
 implies that some studies require precision medicineズ
Liberati Aゴ Altman DGゴ Tetzlaff Jゴ Mulrow Cゴ Gqtzsche Pゴ et alズ ┑≦＜＜′┒ The PRISMA
statement for reporting systematic reviews and metaゾanalyses of studies that




Strongly agreeズ For high correlations between baseline and outcomeゴ it follows that V ┑log
┑V ┄V ┒┒ ４ V ┑log ┑V ┒┒ゴ as can be seen in Appendix VII of the supplementary materialズ
Howeverゴ just ∴＞ out of ＝×∞ studies provide the Var┑change┒ or the baselineゾfinal
correlation that would allow this analysisズ 
≦ズ It may be of interest to perform a subgroup analysis in the studies where control is placebo
In factゴ we performed this subgroup analysis beforehand without obtaining relevant
resultsズ We decided not to include or mention it because the distinction between a
treatment called どplaceboど and an どactiveど treatment is not clearズ プPlaceboベ is defined as
a simulator of the experimental treatment that tries to emulate its characteristicsザ but in
some studies プcontrolベ may equal プbest medical treatmentベゴ which is also provided to
プtreatedベ patientsゴ such that プPlaceboベ is complemented by the standard interventionズ
Because of this ambiguity in the classificationゴ we decided to omit this informationズ As
illustrative examplesゴ we mention the following included studiesジ 
ゾ Ghaleiha Aゴ Mohammadi Eゴ Mohammadi Mゴ et alズ Riluzole as an adjunctive therapy to
risperidone for the treatment of irritability in children with autistic disorderジ a
Thedoubleゾblindゴ placeboゾcontrolledゴ randomized trialズ Paediatr Drugs ≦＜＞≧ ＞∴ジ∴＜∴┆∴＞∞ズ 
patients in the reference group took placebo in addition to risperidone ┑titrated up to ＝ or
≠ mg┄day based on bodyweight┒ for ÷× weeksズ
ゾ Carroll MWゴ Jeon Dゴ Mountz JMゴ et alズ Efficacy and safety of metronidazole for pulmonary
Ox Bx Ox
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ゾ Carroll MWゴ Jeon Dゴ Mountz JMゴ et alズ Efficacy and safety of metronidazole for pulmonary
ズ Themultidrugゾresistant tuberculosisズ Antimicrob Agents Chemother ≦＜＞≧ザ ∴♀ジ≧′＜≧ゾ′






Thank youズ We have corrected the typo including the subscript both in the Methods




Thanksズ Tau reflects the heterogeneity in the assessment of the heteroscedasticity
throughout the studiesズ Following this suggestion and similar comment of Professor Ian
Whiteゴ we have tried to clarify that mu is a measure of heteroscedasticity and tau is a
measure of the heterogeneity of the former throughout all the studiesズ See also the
answer to question ＜ for more clarificationズ
∴ズ Supplementary Table S＜ズ Why not put this Table in Section ＜ゴ and make one overview of all the
models fittedバ And I guess that eたij should be eたi hereズ
Thank youゴ we have corrected the subscript typoジ プeたiベ
And yesゴ your suggestion facilitates readabilityズ We have interspersed all the tables and
figures of the supplementary material in their respective sectionsズ
÷×ズ Resultsジ I did not find Figure S÷ and Figure S＝ very informativeズ Why not just give a histogram
of log┑varたOT┄varたCT┒ etcズ
We have kept Figures S÷ and S＝ because we believe that they provide additional
information about whether or not the increase ┑or decrease┒ in the variability in the
outcome of the experimental arm depends on the outcome variability of the control arm
┑or on the baseline variability of the experimental group┒ズ Howeverゴ we have also added
the histograms you mention in order to summarize the essential informationズ The
histograms can be seen here or in the Supplementary materialズ
÷÷ズ Table ÷ジ How were the results from the random model obtained ┑the ÷÷ increasedゴ ÷∴
decreased etc┒バ
We have obtained them as the studies that had to be removed in order to obtain
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We have obtained them as the studies that had to be removed in order to obtain
heterogeneity ┑iズeズゴ tau┒ similar to the baseline ┑which we expect to be null by
randomization┒ズ We have tried to clarify this point in the legend of the tableジ
プゼor ┑＝┒ number of studies that have to be deleted from the randomゾeffects model in
order to achieve a negligible heterogeneity ┑studies with more extreme outcome were
removed one by one until achieving an estimated value of 】 similar to the one obtained
from the reference modelズ See Methods section for more detailsゼ┒ベ
÷＝ズ Figure ≠ズ Please explain what VたOTゴ VたOC etc isゴ as Figures should be selfゾexplainedズ
Thanksズ We have included a legend in this figure explaining these abbreviationsジ
VっOTジ Variance of the Outcome in the Treated arm
VっOCジ Variance of the Outcome in the Control arm





You are rightズ We say プnonゾobservableベ for the fundamental problem of causal inference
┑both potential responses are not observable in the same patient┒ゴ which avoids seeing
the treatment effect at the individual levelズ We have clarified this pointジ
Beforeジ This means that treatment effects obtained by comparing the means between
groups can be used to estimate both the averaged treatment effect and the
nonゾobservable patient treatment effectズ
Afterジ This means that the average treatment effect can be interpreted as an individual
treatment effect ┑not directly observable┒ズ
÷＜ズ Shocking to see that so many studies do not report measures of variabilityズ
Yesズ It is really surprising that ≦÷ズ≦† of studies do not report the variability either at
baseline or at the end of the studyズ Although CONSORT advises itゴ this guideline does not




We are referring to the main analysisジ comparison between armsズ Neverthelessゴ this
sentence could be applied to all analysesズ Heterogeneity among studies is measured by
tau ┑see response to question ＜┒ズ 
We stated that methodological inaccuracies can be derived in the presence of
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We stated that methodological inaccuracies can be derived in the presence of
heterogeneityズ In an ideal scenario of constant treatment effect in all the studiesゴ the only
thing that could lead to heterogeneity in the model would be methodological inaccuracies
such as those mentioned in the manuscript or in the referenced paper of Carlisleジ
transcription errorsゴ insufficient followゾup time for being able to observe this constant








Fully agreeゴ although this is a highly sophisticated scenario that we hope will not be
viewed as a frequent scenarioズ
Of courseゴ we think that personalized medicine has already been demonstrated to be
effective in some areasズ Our point is that unless those demonstrations existゴ most
 interventions should be routinely administrated to all patients fulfilling eligibility criteriaズ
 No competing interests were disclosedズCompeting Interestsジ
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about previous patients   to learn about future similar patientsズwith particular characteristics
Is the work clearly and accurately presented and does it cite the current literatureバ
Partly
Is the study design appropriate and is the work technically soundバ
Partly
Are sufficient details of methods and analysis provided to allow replication by othersバ
Yes
If applicableゴ is the statistical analysis and its interpretation appropriateバ
Partly
Are all the source data underlying the results available to ensure full reproducibilityバ
Yes




I have read this submissionズ I believe that I have an appropriate level of expertise to state that I
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Is the work clearly and accurately presented and does it cite the current literatureバ
No
Is the study design appropriate and is the work technically soundバ
Yes
Are sufficient details of methods and analysis provided to allow replication by othersバ
Yes
If applicableゴ is the statistical analysis and its interpretation appropriateバ
No
Are all the source data underlying the results available to ensure full reproducibilityバ
Yes
Are the conclusions drawn adequately supported by the resultsバ
No
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I have read this submissionズ I believe that I have an appropriate level of expertise to confirm that




JOINT ANSWER to Ian White and Saskia le Cessie
This is a general response to Ian White and Saskia Le Cessie on why we stated that the
standard clinical trial design and analysis assume a constant effectズ
In the followingゴ ┑÷┒ we update the standard sample size rationaleザ and ┑＝┒ we explain why
inflated variances may require precision medicine in just two general casesジ ┑a┒
interactionゴ as represented in Figズ ÷ゴ panel Cザ and ┑b┒ random treatment effectゴ Figズ ÷ゴ
panel Dズ
Under the NeymanゾPearson framework to determine sample sizeゴ a single effect
size value ┥ is specified under the alternative hypothesis H÷ゴ assuming in that way
a constant effectゴ as in Figズ ÷ゴ panels A ┑H×┒ and B ┑H÷┒ズ
We devise two situations thatゴ because they result in higher varianceゴ they would
need personalized medicineジ
Interaction between treatment and a baseline variable such usゴ for exampleゴ
gender ┑Figズ ÷ゴ panel C┒ズ In this scenario there are two subpopulations ┑eズgズゴ
men and women┒ with different treatment effects that require the effect to be
made further プpreciseベズ
Random treatment effect on each patient ┑Figズ ÷ゴ panel D┒ズ In this scenarioゴ
the effect size does not depend on a known patient baseline characteristic
and the only way to estimate the individual patient effect is by means of
individualized trials ┑プn of ÷ベ trials┒ズ
 
Those ＝ hypothetical scenariosゴ lead to an increased varianceズ Converselyゴ scenarios E
and F represent two similar situations ┑interaction and random effect┒ but result in
reduced variance ┆without relevant changes on the averageズ Although we agree that in
those two last scenarios leading to reduced variability the specific patient treatment effect
may still be unknown because the outcome has reduced variability with a similar central
overall positionゴ we argue that patients in those situations were subject to プfurther
controlベ ┑having more stable values within the boundaries of プnormalityベ┒ズ 
Soゴ the usual sample size rationale specified by statisticians in trials assumes a constantゴ
unique effect that agrees with the clinical and legal interpretation that the effect is the
same ┆ or at least similar enough to be considered homogeneous ┆ for all the patients
fulfilling the eligibility criteriaズ 
To illustrate this secondary プargumentベゴ we reviewed the sample size rationale for the last
┑at that time┒ ÷× protocols published in Trialsゴ and we found that all of them defined a
single effect size ┑÷××†ゴ twoゾsided ∴＞† confidence interval from ≦∴† to ÷××†┒ズ In
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┑at that time┒ ÷× protocols published in Trialsゴ and we found that all of them defined a
single effect size ┑÷××†ゴ twoゾsided ∴＞† confidence interval from ≦∴† to ÷××†┒ズ In
additionゴ we have included a new column in Table S÷ with the main analysis showing that
the SAP in all those cases ┑÷× out of ÷×ゴ ∴＞†CI from ≦∴ to ÷××†┒ was also designed to
estimate a singleゴ constant effectズ
We have modified Figズ ÷ ┑panels E and F┒ to show decreasing variance treatment effectsゴ
but now without affecting the averageズ We have also improved the ＝ following sentencesジ
Before ┕Abstract┖ジ Howeverゴ the conventional design of randomized trials assumes that
each individual benefits by the same amountズ
After ┕Abstract┖ジ Howeverゴ conventional clinical trials are designed to find differences with
the implicit assumption that the effect is the same in all patients within the eligibility
criteriaズ
Before ┕Introduction┖ジ The assumption that the average effect equals the single unit effect
underlies the rationale behind the usual sample size calculationゴ where only a single
effect is specifiedズ As an exampleゴ the ÷× clinical trials published in the Trials Journal in
October ＝×÷≧ ┑see Supplementary materialジ Table S÷┒ were designed under this scenario
of a fixedゴ constant or unique effect in the sample size calculationズ
After ┕Introduction┖ジ The assumption of homoscedasticity in the usual calculations of
sample size is better interpreted under the constant effect model ┑Figure ÷ゴ panels Aゴ H ザ
and Bゴ H ┒ズ As an exampleゴ the ÷× clinical trials published in the Trials Journal in October
＝×÷≧ ┑Table S÷ of Supplementary material┒ were designed with only a constant for the
effect sizeズ Furthermoreゴ all their analyses were designed to test ┑and estimate┒ a single
constant for the effect sizeズ In other wordsゴ there was mention of neither any possible
interaction with baseline variables ┑Figure ÷ゴ scenarios C and E┒ゴ nor of any random
variability for the treatment effect ┑Figure ÷ゴ scenarios D and F┒ザ and thusゴ all those trials
were designed to test a constant effectズ
We have also updated the legend of Figure ÷ to highlight that now panels C to F show only
possible individual treatment effects on variances but not on meansズ
We are deeply grateful to Ian White and Saskia le Cessie for highlighting the need to
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Thanks again for highlighting this hugely important issueズ We have addressed these two









Thanksズ To simplify the notationゴ we have deleted the term プconcordanceベズ We also
reserved the term heterogeneity for the tau／＝ statistic resulting from the mixedゾeffects
model ┑see next answer┒ズ Furthermoreゴ we have homogenized the terms for referring to




We appreciate this insightful observationズ In the randomゾeffects modelゴ we measured
heteroscedasticity with the mu parameterゴ and heterogeneity between studiesゴ through
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heteroscedasticity with the mu parameterゴ and heterogeneity between studiesゴ through
tau／＝ズ In order to clarify this as much as possibleゴ we have specified in the Methods
section that tau／＝ is used for measuring heterogeneityザ and this has also been included
between brackets in the Results sectionジ
プThe estimated value of tau／＝ provides a measure of heterogeneityゴ that isゴ to what extent




We used the Delta method to estimate the within study variability ┑specificallyゴ the
variance of the logarithm of the outcome variance ratio┒ズ We have included this
explanation in the Methods sectionジ プAs there is only one available measure for each
studyゴ both sources of variability cannot be empirically differentiatedジ ┑i┒ within study or
random or that one related to sample sizeザ and ┑ii┒ heterogeneityズ In order to isolate the
secondゴ the first was theoretically estimated using the Delta method ┆as explained in







Thanks for this great contributionズ Following your suggestionゴ we have sought in each
primary endpoint for whether improvements in the response correspond to higher ┑eズgズゴ
mobility┒ or lower ┑eズgズゴ pain┒ valuesズ This new factor has been included in the subgroup
analysis ┑see new figures S＞ゾS≧ clicking here or in the Supplementary Material┒ゴ thus
providing an argument for the existence of a どfloorど effect in those studies where a lower
value corresponds to a better conditionズ We have added an interpretation of this finding in
the Discussionジ
プThis reduced variability could also be due to methodological reasonsズ One is that some
measurements may have a プceilingベ or プfloorベ effect ┑eズgズゴ in the extreme caseゴ if a
treatment heals someoneゴ no further improvement is possible┒ズ In factゴ according to the
subgroup analysis of the studies with outcomes that indicate the degree of disease ┑high
values imply greater severityザ eズgズゴ pain┒ゴ a greater variance ┑＝＞†┒ is obtained in the
experimental arm ┑see Figure S＞┒ズ Howeverゴ in the studies with outcomes that measure
the degree of healthiness ┑high values imply better conditionザ eズgズゴ mobility┒ゴ the average
variances match between arms and do not suggest a ceiling effectズベ
In additionゴ we have included this new factor ┑direction of the improvement┒ in the Shiny
appズ
On the other handゴ all the significant studies were in favor of the experimental groupザ
thereforeゴ in our contextゴ どstatistically significantど is equivalent to どbetter response in the
Page ＞≠ of ＞∴
F÷×××Research ＝×÷∴ゴ ≧ジ≠× Last updatedジ ÷＝ JUN ＝×÷∴
 
thereforeゴ in our contextゴ どstatistically significantど is equivalent to どbetter response in the
experimental groupどズ We have specified this statement in the manuscript and we have
kept the sentenceジ どthe authors found statistically significant differences between the




Thanksズ Corrected both in the Abstract and the main textジ
Before ┕Abstract┖ジ We assessed homoscedasticity by comparing the outcome variability
between treated and control arms
After ┕Abstract┖ジ We assessed homoscedasticity by comparing the variance of the primary
endpoint between arms through the outcome variance ratio ┑treated to control group┒ズ
Before ┕Abstract┖ジ The adjusted point estimate of the mean ratio ┑treated to control group┒
After ┕Abstract┖ジ The adjusted point estimate of the mean outcome variance ratio ┑treated
to control group┒ ゼ
Before ┕Methods┖ジ ゼ we fitted a randomゾmixed effects model using the logarithm of the
variance ratio at the end of the trialゼ
After ┕Methods┖ジ ゼ we fitted a randomゾeffects model using the logarithm of the outcome
variance ratio at the end of the trial ゼ
≦ズ ┝Table ÷ゴ プvariability isゼ increasedベジ from the textゴ this means プsignificantly increasedベゴ which
should be clarifiedズ
Thanksズ We have corrected itジ
Before ┕Table ÷┖ジ increased┄decreased
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Thanks againズ We have dealt with this in the Discussionジ
プゼit has been observed that the variability in the experimental arm also decreases from
baseline to the end of the studyゴ although this comparison is not protected by
randomizationザ for exampleゴ the existence of eligibility criteria at baseline may have
limited the initial variance ┑a hypertension trial might recruit patients with baseline SBP










Thanksズ We agreeズ We have addressed this point in the general response aboveズ We
provide here further specific commentsズ
There is heteroscedasticity of effect leading to reduced outcome variabilityゴ such as the
one shown in examples E and F of Figure ÷ズ Those cases with reduced variability show
situations in which the outcome is プunder additional controlベ at the endズ The only
mathematical model that we can imagine here is the one with an effect correlated with
baseline valuesジ higher effects for higher ┑worse┒ baseline valuesズ We can imagine this
situation for the プidealベ training programジ worse participants at the beginningゴ which
further increases or reduces variabilityズ Soゴ although we agree that this is a theoretical
heterogeneityゴ we do not think that it has any practical implication for プindividualizingベ the
treatmentジ all patients benefit ┑although to a different degree┒ from the interventionザ and at
the endゴ all patients are プunder additional controlベズ
We have performed some changes in the manuscript in order to clarify this pointジ
Before ┕Abstract┖ジ the variance was more often smaller in the intervention groupゴ
suggestingゴ if anythingゴ a reduced role for precision medicine
After ┕Abstract┖ジ We found that the outcome variance was more often smaller in the
intervention groupゴ suggesting that treated patients may end up pertaining more often to
reference or プnormalityベ values and thus would not require further precision medicineズ
Howeverゴ this result may also be compatible with a reduced effect in some patientsゴ which
would require studying whether the effect merits enduring the side effects as well as the
economic costsズ 
Before ┕Discussion┖ジ variability tends to be reduced on average after treatmentゴ thus
making precision medicine dispensable in most cases
After ┕Discussion┖ジ We found that variability seems to decrease for treatments that
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After ┕Discussion┖ジ We found that variability seems to decrease for treatments that
perform significantly better than the referenceザ otherwiseゴ it remains similarズ Thereforeゴ
the treatment seems to be doing what medicine should do ┆having larger effects in the
most ill patientsズ Two considerations may be highlighted hereジ ┑÷┒ as the outcome range
becomes reducedゴ we may interpret thatゴ following the interventionゴ this population is
under additional controlザ but alsoゴ ┑＝┒ as subjects are responding differently to treatmentゴ
this opens the way for not treating some ┑eズgズ those subjects who are not very illゴ and so




In this caseゴ we have softened the sentence by changing the term どneedど to どevidenceどズ
Before ┕Introduction┖ジ If this homoscedasticity holdsゴ there is no need to repeat the clinical
trial once a new possible effect modifier becomes measurable
After ┕Introduction┖ジ If this homoscedasticity holdsゴ there is no evidence that the clinical




We are not sure that we understood why this is illogicalズ Anywayゴ we have softened the
sentence by changing どan obvious default explanationど to どthe simplest explanationどズ
Before ┕Discussion┖ジ When both arms have equal variancesゴ then an obvious default
explanation is that the treatment is equally effective for allゴ thus rendering the search for
predictors of differential response futile
After ┕Discussion┖ジ When both arms have equal variancesゴ then the simplest explanation is





Againゴ we are not sure that we understood why this is illogicalズ Neverthelessゴ we have
referred to the limitations derived from Figure ＜ズ
Before ┕Discussion┖ジ For most trialsゴ subjects vary little in their response to treatmentゴ
which suggests that precision medicineブs scope may be less than what is commonly
assumed
After ┕Discussion┖ジ For most trialsゴ variability of the response to treatment changes
scarcely or even decreasesゴ which suggests that precision medicineブs scope may be less
than what is commonly assumed ┆ while always taking into account the limitation
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We have reduced the ostentatious nature of this phraseゴ warning the reader that there are
limitations to this methodologyジ
プWe have shown that the comparison of variances is a useful but not definitive tool to
asses if the design assumption of a constant effect holdsズベ
＜ズ ┝The objectives in the Discussion should be the same as those stated in the Introductionズ
Thanksズ We have simplified the objectives in the introductionジ
Beforeジ Our objectives wereゴ firstゴ to compare the variability of the main outcome between
different arms in clinical trials published in medical journals andゴ secondゴ to provide a
firstゴ rough estimate of the proportion of studies that could potentially benefit from
precision medicineズ As sensitivity analysisゴ we explore the changes in the experimental
armブs variability over time ┑from baseline to the end of the study┒ズ We also fit a randomゾ
effects model to the outcome variance ratio in order to isolate studies with a variance
ratio outside their expected random variability values ┑heterogeneity┒ズ
Afterジ Our objectives wereゴ firstゴ to compare the variability of the main outcome between
different arms in clinical trials published in medical journals using a randomゾeffects
modelザ andゴ secondゴ to provide a rough estimate of the proportion of studies that could
potentially benefit from precision medicineズ Finallyゴ we explore the changes in the
experimental armブs variability over time ┑from baseline to the end of the study┒ズ
 
Alsoゴ we have reordered the whole Discussion section according to these objectivesジ 
÷┒ Variability comparison between arms and explanation
 
＝┒ Rough estimate of the studies that potentially benefit from precision medicine ┑greater
variability in experimental arms┒
 







We have changed the format ┑nowゴ columns are commaゾdelimited┒ both in the Shiny app
and in the Figshare repositoryズ We also solved the problem with line ∞×ゴ which included
 some unnecessary quotation marks ┑プ┒ in the  fieldズTitle
 No competing interests were disclosedズCompeting Interestsジ
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